TScan Therapeutics’ (TCRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report report published on Wednesday morning, Marketbeat Ratings reports. HC Wainwright also issued estimates for TScan Therapeutics’ FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.91) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at ($0.16) EPS.

Several other research analysts have also issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.00.

TScan Therapeutics Price Performance

TScan Therapeutics stock opened at $0.78 on Wednesday. The firm has a 50-day moving average price of $0.90 and a 200-day moving average price of $1.01. The firm has a market capitalization of $50.89 million, a PE ratio of -0.86 and a beta of 1.06. The company has a current ratio of 3.37, a quick ratio of 6.65 and a debt-to-equity ratio of 0.31. TScan Therapeutics has a 12-month low of $0.72 and a 12-month high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.88 million. As a group, equities research analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

Hedge Funds Weigh In On TScan Therapeutics

A number of institutional investors have recently modified their holdings of TCRX. Landscape Capital Management L.L.C. bought a new stake in shares of TScan Therapeutics during the second quarter valued at approximately $25,000. Panagora Asset Management Inc. bought a new position in TScan Therapeutics in the fourth quarter worth approximately $25,000. HRT Financial LP purchased a new position in TScan Therapeutics during the 4th quarter worth $26,000. Public Employees Retirement System of Ohio purchased a new position in TScan Therapeutics during the 1st quarter worth $28,000. Finally, Boothbay Fund Management LLC increased its holdings in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the period. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics News Roundup

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on TScan Therapeutics, offering some support for the stock despite the firm’s lower earnings projections. TScan Therapeutics Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Brokerage coverage overall was described as carrying a consensus rating of Hold, suggesting analysts remain cautious and that HC Wainwright’s Buy rating is not broadly shared. TScan Therapeutics Given Consensus Rating of Hold
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across every year from FY2026 through FY2030: estimates were reduced to losses of $0.91, $0.89, $0.91, $0.80 and $0.16 per share, respectively. The revisions indicate the analyst expects a slower path toward profitability, despite retaining the Buy rating. Analysts Offer Insights on Healthcare Companies Including TScan Therapeutics

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.